pbio.3002544.s010.pdf (331.94 kB)
Pre-treatment and post-treatment using compounds.
journal contribution
posted on 2024-02-29, 18:53 authored by Carlos A. Rodríguez-Salazar, Sarah van Tol, Olivier Mailhot, Maria Gonzalez-Orozco, Gabriel T. Galdino, Abbey N. Warren, Natalia Teruel, Padmanava Behera, Kazi Sabrina Afreen, Lihong Zhang, Terry L. Juelich, Jennifer K. Smith, María Inés Zylber, Alexander N. Freiberg, Rafael J. Najmanovich, Maria I. Giraldo, Ricardo Rajsbaum(A, B) Ebola titers obtained from virus yield reduction assay expressed in Log10 by pfu/ml. (B) Ebola titers obtained from Plaque reduction assay expressed in Log10 by pfu/ml, shown in Fig 7D and 7E. Data are depicted as mean + SEM. One-Way ANOVA Tukey’s multiple comparisons test. (C) Pre-treatment with pCEBS and SFC do not affect EBOV replication. Fluorescent microscopy of Vero CCL81 cells untreated or treated with 200 μm of pCEBS or SFC for 1 h, compounds were removed, and cells were infected with EBOV-GFP MOI 0.01. The data underlying the graphs shown in the figure can be found in S1 Data.
(PDF)
History
Usage metrics
Categories
Keywords
xlink "> ebolavirususing computational methodshighly pathogenic virusescompounds reduced replicationalso interact nonub interacting surfaceub ); howeverviral polymerase complexreduced vp35 associationinterferon antagonist vp35covalent interacting complexlinked polyub chainsebov replication requiresub interactions leadingdiminished polymerase activitypolymerase complexub nonregulating interactionsdiscovered compoundscovalent ubiquitinationvp35 interactsblock vp35usp5 ),unanchored polyububiquitin chainstested mutationspromising antipreviously showednovel rolemouse modelminigenome assayinfectious ebovectopic expression
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC